Tags : P-III CLL-14 study

Roche Reports Results of Venclexta/Venclyxto plus Gazyva/Gazyvaro in P-III CLL-14

Vartika Singh November 1, 2018

Shots: The P-III CLL-14 study involves assessing of Venclexta (venetoclax) + Gazyva (obinutuzumab) vs Gazyva + chlorambucil in 432 1L CLL patients The study included 1EP as PFS and 2EP […]readmore

Tags : P-III CLL-14 study

Roche Reports Results of Venclexta/Venclyxto plus Gazyva/Gazyvaro in P-III CLL-14

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : P-III CLL-14 study

Roche Reports Results of Venclexta/Venclyxto plus Gazyva/Gazyvaro in P-III CLL-14

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company